Henry Schein Inc Dossier
Qualitative Analysis
Business overview
Henry Schein, Inc. (NASDAQ: HSIC) is the world's largest provider of healthcare products and services to office-based dental and medical practitioners. Headquartered in Melville, New York, and founded in 1932, the Fortune 500 company operates a vast global distribution network spanning 34 countries and territories. Henry Schein serves more than 1 million customers globally through its three primary segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. The company's comprehensive portfolio includes over 300,000 solutions, ranging from dental consumables and medical-surgical supplies to practice management software and clinical workflow tools powered by artificial intelligence.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive strategic plan focused on accelerating growth, enhancing digital capabilities, and transforming the company into a more agile, customer-centric, and efficient organization.
Expected impact: Aims to achieve high-single-digit to low-double-digit earnings growth and targets over 50% of non-GAAP operating income coming from high-growth, high-margin businesses (such as software, specialty, and services) by the end of 2027.
Operational efficiency initiatives including centralizing certain support services, pricing optimization, and accelerating corporate brand sales through centralized digital infrastructure.
Expected impact: Expected to deliver over $200 million of annual operating income improvement over the next few years, with a $125 million run-rate achieved by the end of 2026.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired a controlling interest in its S.I.N. distributor in the U.S. to enhance its position in the fast-growing value implant market and support its business integration strategy.
Financial impact: Provides greater control over the U.S. implant product portfolio and unlocks back-office integration efficiencies. The transaction resulted in an $11 million remeasurement gain in Q1 2026.
Acquisition of a provider of vaccines, medical-surgical products, and equipment to Hawaii-based health care facilities and practitioners to expand geographic footprint and grow the customer base.
Financial impact: Strengthens presence across the Hawaiian Islands and leverages the acquired company's 2024 sales of approximately $11 million.
Acquisition of a specialist in Continuous Glucose Monitors and vital medical supplies delivered directly to homes to expand the home medical supplies market footprint.
Financial impact: Projected to be neutral to 2025 non-GAAP earnings per share and accretive thereafter, increasing annual revenue in the homecare segment to over $350 million.